Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
296
-
Total 13F shares, excl. options
-
50.6M
-
Shares change
-
+15.4K
-
Total reported value, excl. options
-
$4.33B
-
Value change
-
-$1.42M
-
Put/Call ratio
-
0.43
-
Number of buys
-
119
-
Number of sells
-
-154
-
Price
-
$85.51
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2023
344 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2023.
HAEMONETICS CORP - Common Stock (HAE) has 296 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.6M shares
.
Largest 10 shareholders include Capital Research Global Investors (6.52M shares), BlackRock Inc. (6.04M shares), VANGUARD GROUP INC (5.41M shares), NEUBERGER BERMAN GROUP LLC (3.53M shares), WELLINGTON MANAGEMENT GROUP LLP (3.27M shares), STATE STREET CORP (1.79M shares), FRANKLIN RESOURCES INC (1.69M shares), FMR LLC (1.58M shares), T. Rowe Price Investment Management, Inc. (1.09M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.09M shares).
This table shows the top 296 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.